Regulatory & Legal

With a massively oversubscribed bond offering, Canada's leading alternative lender signals its rapid ascent into the financial mainstream. Here's what it means.

With the launch of Steelforce America, the global steel firm appoints a new CEO to capture growth in a dynamic, multi-billion dollar market.

With a record 8 million kg of batteries collected in 2025, Canada is winning its fight against waste. See how local efforts are paving the way for an EV future.

With its stock under pressure, Geron will face investors to defend its RYTELO sales strategy and address delays in its pivotal myelofibrosis trial.

Outdoor Holding Co. ends a major legal distraction with a $4.4M payment, allowing it to fully focus on innovating its GunBroker.com marketplace.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.

OptimumBank Holdings leverages its deep expertise in healthcare and multifamily real estate by launching OptimumFunding, a new HUD and FHA lending platform.

Verrica Pharmaceuticals heads to a key investor conference with strong YCANTH sales, a promising pipeline for warts and skin cancer, and high expectations.

A brief delay in Avidity's stockholder vote signals the final, complex steps before its acquisition by Novartis and the launch of a new spin-off.

After halting all R&D, PCI Biotech proposes dissolution and delisting, marking the end for its novel drug delivery platform and a warning for investors.

Madison Capital Group offers a new DST for a luxury Asheville community, tapping a hot market facing a surge in supply and evolving economic crosscurrents.

Following a series of acquisitions, Southwest Strategies Group rebrands as Bodewell, positioning itself to manage public consent for a new era of US infrastructure.

With stellar trial data and a fast-tracked FDA submission, CG Oncology prepares for a pivotal presentation at the TD Cowen Health Care Conference.

iRegene Therapeutics hits dual milestones, advancing AI-derived cell therapies for Parkinson's in the US and Multiple System Atrophy in China.

A landmark FDA approval for Bracco's VUEWAY allows high-quality MRI scans in neonates with half the standard gadolinium dose, easing safety concerns.

New 12- and 24-month data for Benitec Biopharma's BB-301 gene therapy offers renewed hope for patients with a rare, debilitating muscular dystrophy.

Anavex Life Sciences adds AMEOS Group CEO Dr. Axel Paeger to its board, a strategic move signaling a push into European markets for its CNS therapies.

With a key drug in trials and a pipeline nearing the clinic, Foghorn Therapeutics brings in a seasoned financial leader to navigate its path to market.

An Israeli-Brazilian partnership aims to deploy novel gene technology to protect vital corn harvests in South America from devastating drought.

The biotech firm slashed a major acquisition hurdle in a deal with HealthCare Royalty, signaling strong confidence in its cancer drug ZYNLONTA's future.